EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieRandomisierte kontrollierte Studie

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

Thomas L Holland iD, Sara E Cosgrove iD, Sarah B Doernberg, Timothy C Jenkins, Nicholas A Turner, Helen W Boucher, Oleksander Pavlov, Ivan Titov, Serhii Kosulnykov, Boyko Atanasov, Ivan Poromanski, Manana Makhviladze und 12 weitere

New England Journal of Medicine · 12.10.2023 · 389 (15) · 1390-1401

DOI: 10.1056/nejmoa2300220 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 12.10.2023. Verfasst von Thomas L Holland und 23 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Infectious Diseases, Duke University (T.L.H., N.A.T., V.G.F.), and Duke Clinical Research Institute (T.L.H., V.G.F.) - both in D…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Daptomycin, Staphylococcal Infections. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Basilea Pharmaceutica, U.S. Department of Health and Human Services, Basilea Pharmaceutica International Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaDaptomycinStaphylococcal InfectionsStaphylococcus aureusAdultHumansCephalosporinsMethicillin-Resistant Staphylococcus aureusTreatment OutcomeDouble-Blind MethodAdministration, IntravenousAztreonam

Substanzen

Anti-Bacterial AgentsceftobiproleCephalosporinsDaptomycinAztreonam

Autor:innen und Institutionen

  • From the Division of Infectious Diseases, Duke University (T.L.H., N.A.T., V.G.F.), and Duke Clinical Research Institute (T.L.H., V.G.F.) - both in Durham, NC; the Department of Medicine, Johns Hopkins University School…

ORCID-Profile: Thomas L Holland, Sara E Cosgrove, Kamal Hamed

Förderung

  • Basilea Pharmaceutica
  • U.S. Department of Health and Human Services
  • Basilea Pharmaceutica International Ltd
  • Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development…

Zitieren

APA

Holland, T. L., Cosgrove, S. E., Doernberg, S. B., Jenkins, T. C., Turner, N. A., Boucher, H. W., Pavlov, O., Titov, I., Kosulnykov, S., Atanasov, B., Poromanski, I., Makhviladze, M., Anderzhanova, A., Stryjewski, M. E., Assadi Gehr, M., Engelhardt, M., Hamed, K., Ionescu, D., Jones, M., …, & ERADICATE Study Group (2023). Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. New England Journal of Medicine, 389(15), 1390-1401. https://doi.org/10.1056/nejmoa2300220

Vancouver

Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, et al. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. New England Journal of Medicine. 2023;389(15):1390-1401. doi:10.1056/nejmoa2300220

BibTeX
@article{Holland2023,
  author = {Holland, Thomas L and Cosgrove, Sara E and Doernberg, Sarah B and Jenkins, Timothy C and Turner, Nicholas A and Boucher, Helen W and Pavlov, Oleksander and Titov, Ivan and Kosulnykov, Serhii and Atanasov, Boyko and Poromanski, Ivan and Makhviladze, Manana and Anderzhanova, Anastasia and Stryjewski, Martin E and Assadi Gehr, Maziar and Engelhardt, Marc and Hamed, Kamal and Ionescu, Daniel and Jones, Mark and Saulay, Mikael and Smart, Jennifer and Seifert, Harald and Fowler, Vance G and ERADICATE Study Group, ERADICATE Study Group},
  title = {Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {15},
  pages = {1390--1401},
  doi = {10.1056/nejmoa2300220}
}
Kostenlos starten →